newsfilter
← Latest News
PR Newswire·

Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Continues to Advance Preparations for Potential U.S. Commercial Launch of Teplizumab Ahead of November 17th FDA User Fee Goal Date RED BANK, N.J., Nov. 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a